Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A
in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2
virus.